Post Reply
21-40 of 88
yeah, so much cash, no debt
plus annually a lot of cash generation.
should do SBB.
plus annually a lot of cash generation.
should do SBB.
The market cap needs to recover to ~US$1.6b or > S$2b which is the requirement for Nasdaq listing but more importantly, what would be the use of those proceeds? They have been cash flow positive so unless they put their cash raised from SGX IPO to work more and have a need to raise additional equity with the Nasdaq listing for growth capital else it would be dilutive to shareholders.
Would want to see them start giving some dividends or at least support share price with share buyback.
Would want to see them start giving some dividends or at least support share price with share buyback.
alexvar ( Date: 06-May-2026 11:21) Posted:
|
Watching this counter since yesterday and today..gone down despite good news and fundamentals. Niche counter.
pretty amazing!
Next would be cool to see them getting secondary listed on Nasdaq - when and how would it be possible?
since America is their largest market.
Next would be cool to see them getting secondary listed on Nasdaq - when and how would it be possible?
since America is their largest market.
Joelton ( Date: 06-May-2026 09:30) Posted:
|
UltraGreen.ai secures regulatory approval for Verdye in Singapore
UltraGreen.ai (SGX:ULG) announced that it secured regulatory approval for Verdye (indocyanine green for injection) in Singapore.
The company believes this approval is a strategic step in its Southeast Asia growth strategy, which will help in expanding its addressable market and strengthening its presence in a key regional healthcare hub.
&ldquo Singapore plays a critical role as a centre for clinical excellence and regional influence, supporting broader adoption of advanced surgical technologies across Southeast Asia,&rdquo the company adds.
Through the approval, it will enable Utragreen.ai to advance commercialisation efforts, deepen partnerships with leading healthcare institutions, and support clinical adoption of fluorescence-guided surgery.
&ldquo This approval reinforces our strong regulatory execution and clear momentum in our regional strategy. We are well positioned to support surgeons with proven fluorescence-guided solutions while laying the groundwork for continued growth and innovation across Southeast Asia,&rdquo says Ravi Sajwan, CEO of Ultragreen.ai.
at least they r watching...
YewTee ( Date: 05-May-2026 23:06) Posted:
|
go up 8 cents, next day go down 10 cent....keep kana short......management just watch.....
Only makes sense if they buy back at current or lower valuations and then issue new shares on Nasdaq at higher multiples - at least in a textbook and ideal setting, if Mr Market permits. For now, they need to get the right investors and eyeballs on the stock. A rare healthcare and growth stock yet share price continues to underperform.
investshare ( Date: 05-May-2026 16:22) Posted:
|
Also , during the last AGM if any of your guys attended . The board are considering paying out dividend for the share . yes the buy back of share has been approved during the AGM. not sure why still letting other to short the share to below IPO prices . very embrassing. this is a rare stock and please look at long term and not short term . it is actually a live saving product for a lot of sick people. Hope the share will surge to TP soon .
this share is sleeping . other stocks have surge so much and yet this share still below IPO price .
what a joke . Still dare to drop 10 cents after the business plan is out .
Where is the buy back ler .
what a joke . Still dare to drop 10 cents after the business plan is out .
Where is the buy back ler .
I thought they plan dual listing on nasdaq, buy back share does not seem make sense.
only when they feel they need to defend the price or they feel shares are undervalued. They will not do share buybacks when you and me feel they should. The mngt knows best and you can always track their share buybacks when they post it. Only when the company has spare cash and knows that it is not adding any value will they initiate a buyback . Ultragreen is not yet there. Most companies will take a buyback mandate in AGM and keep it in their backpocket. There has hardly ever been a share buyback mandate rejection.
alexvar ( Date: 05-May-2026 14:31) Posted:
|
they got SBB mandate, right?
when can they start the share buybacks?
when can they start the share buybacks?
desmlee ( Date: 05-May-2026 11:52) Posted:
|
thats a bit harsh. there are so many stocks that ar euo more than 100%-300% to the past 12-18 months. And then there are stocks like oiltek where if u invested 50k or 100k at IPO, now you would hav retired.
Stocks up and down are all market related and all down to market makers. Who knows ultragreen might be the next oiltek in a few years. You cannot expect Sgx to bahave like US markets, we are too small in size.
Stocks up and down are all market related and all down to market makers. Who knows ultragreen might be the next oiltek in a few years. You cannot expect Sgx to bahave like US markets, we are too small in size.
tongphlp ( Date: 05-May-2026 14:16) Posted:
|
this is SGX remember? results good, drop. results lousy, deeper drop...normal
rise a bit, SGX query...abnormal
rise a bit, SGX query...abnormal
investshare ( Date: 05-May-2026 10:00) Posted:
|
great news with Singapore verdye approval!
also DBS Maintains BUY with TP $2
dydd
also DBS Maintains BUY with TP $2
dydd
They asked for share buyback mandate at AGM. Time to put it to work. Embarrassing for the stock to be under IPO price la
DBS update note
Full-year growth outlook remains intact, supported by ASP and volume growth. We believe Ultragreen is well positioned to meet its revenue target, reflecting the annualisation of higher average selling prices and continued volume growth as ICG adoption expands across procedures. Looking ahead on a quarterly basis, we continue to expect some noise, with 3Q26 likely to show stronger headline y/y growth off a low base, as the softer prior-year quarter reflected a transitional period during the switch from the legacy ICG USP product to IC-GREEN, which took time to fully bed into hospital procurement and distribution systems. In the longer term, Ultragreen remains well positioned to benefit from rising ICG adoption, supported by strong ecosystem growth. Clinical trials have increased 38% since FY23, peer-reviewed publications are up 16% year on year in 2025, and the installed base of robotic systems has tripled between 2015 and 2025. Separately, management highlighted progress in diversifying its lyophilisation network, having expanded from two contractors previously to four currently, with an additional supplier under qualification. This should reduce concentration risk and better support future demand growth. Maintain BUY with TP USD2.00.
1Q26 Business Update: Sequential growth points to healthy underlying demand
- Soft y/y volume is largely a function of a high comparison base rather than a material slowdown in underlying demand
- Full-year growth outlook remains intact, supported by ASP and volume growth
- Secured regulatory approval for Verdye in Singapore, and is pursuing approvals in 20 additional markets
- Maintain BUY with TP USD2.00
Full-year growth outlook remains intact, supported by ASP and volume growth. We believe Ultragreen is well positioned to meet its revenue target, reflecting the annualisation of higher average selling prices and continued volume growth as ICG adoption expands across procedures. Looking ahead on a quarterly basis, we continue to expect some noise, with 3Q26 likely to show stronger headline y/y growth off a low base, as the softer prior-year quarter reflected a transitional period during the switch from the legacy ICG USP product to IC-GREEN, which took time to fully bed into hospital procurement and distribution systems. In the longer term, Ultragreen remains well positioned to benefit from rising ICG adoption, supported by strong ecosystem growth. Clinical trials have increased 38% since FY23, peer-reviewed publications are up 16% year on year in 2025, and the installed base of robotic systems has tripled between 2015 and 2025. Separately, management highlighted progress in diversifying its lyophilisation network, having expanded from two contractors previously to four currently, with an additional supplier under qualification. This should reduce concentration risk and better support future demand growth. Maintain BUY with TP USD2.00.
FOR IMMEDIATE RELEASE ULTRAGREEN.AI SECURES REGULATORY APPROVAL FOR VERDYE IN SINGAPORE, ADVANCING SOUTHEAST ASIA EXPANSION Approval in a strategic healthcare hub strengthens regional growth strategy and supports clinical adoption of fluorescence-guided surgery Singapore, 5 May 2026 &mdash UltraGreen.ai Limited (SGX: ULG) (&ldquo UltraGreen.ai&rdquo or the &ldquo Company&rdquo ), a global leader in fluorescence-guided surgery and digital health solutions, today announced regulatory approval for Verdye (indocyanine green for injection) in Singapore. This approval represents a strategic step in the Company&rsquo s Southeast Asia growth strategy, expanding its addressable market and strengthening its presence in a key regional healthcare hub. Singapore plays a critical role as a centre for clinical excellence and regional influence, supporting broader adoption of advanced surgical technologies across Southeast Asia. This approval enables UltraGreen.ai to advance commercialisation efforts, deepen partnerships with leading healthcare institutions, and support clinical adoption of f luorescence-guided surgery. Fluorescence-guided surgery using ICG is now widely adopted across multiple surgical specialties, including oncology, colorectal, reconstructive, and vascular procedures. Verdye&rsquo s entry into Singapore enhances access to a globally established product with a strong track record across international markets. Scaling an Integrated Fluorescence-Guided Surgery Platform UltraGreen.ai&rsquo s approach extends beyond individual product approvals. The Company continues to build a comprehensive fluorescence-guided surgery ecosystem, combining pharmaceutical products, compatible imaging hardware, and AI-powered data platforms designed to support surgical decision-making, standardisation and improved patient outcomes. It further strengthens the Company&rsquo s ability to scale this platform regionally, supporting longterm growth through increased procedural adoption and recurring product utilisation. Commenting on the approval, Ravi Sajwan, Chief Executive Officer of UltraGreen.ai, said: &ldquo Singapore is a strategically important market for UltraGreen.ai &mdash not only for its world-class healthcare system, but also for its role as a regional reference point for clinical adoption across Southeast Asia. This approval reinforces our strong regulatory execution and clear momentum in our regional strategy. We are well positioned to support surgeons with proven fluorescenceguided solutions while laying the groundwork for continued growth and innovation across Southeast Asia.&rdquo This latest milestone builds on UltraGreen.ai&rsquo s recent IPO and regulatory approval of Verdye in the Philippines, underscoring strong execution and the Company&rsquo s long-term commitment to advancing precision surgery through high-quality pharmaceutical, imaging, and data-driven solutions. Verdye is now approved in 41 countries globally, with the IC-Flow&trade imaging system cleared in 45 markets, reflecting the Company&rsquo s expanding international footprint and ability to scale its integrated fluorescence-guided surgery platform.
Results considered not good?? How come drop?